艾诺佳

Ainuojia (Suzhou) Biotechnology is a clinical-stage biopharmaceutical company specializing in the development of mRNA-based vaccines and therapeutics. The company has established a comprehensive technology platform that integrates mRNA sequence design, modified nucleotide optimization, and proprietary lipid nanoparticle (LNP) delivery systems. Its primary research focus is on infectious disease prevention, with lead programs targeting COVID-19 and respiratory syncytial virus (RSV), alongside a growing pipeline in personalized cancer vaccines. Headquartered in Suzhou's Biobay, Ainuojia leverages its integrated R&D and manufacturing capabilities to advance genomic medicines. The company was founded by industry veterans with extensive experience in global vaccine development and RNA technology.